Equine α-synuclein antibody and antigen (recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-EQU-a-synuclein-Ag01	Recombinant Equine α-synuclein protein	3090
GMP-EQU-a-synuclein-Ab01	Anti-Equine α-synuclein mouse monoclonal antibody (mAb)	1953
GMP-EQU-a-synuclein-Ab02	Anti-Equine α-synuclein mouse monoclonal antibody (mAb)	1953
GMP-EQU-a-synuclein-Ab03	Anti-Equine α-synuclein human monoclonal antibody (mAb)	1953
GMP-EQU-a-synuclein-Ab04	Anti-Equine α-synuclein human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-EQU-a-synuclein-Ag01
Product Name	Recombinant Equine α-synuclein protein
Target/Biomarker	Equine Alpha-synuclein (α-synuclein)
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine Alpha-synuclein antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in α-synuclein level test of animal Equine/Horse with Alzheimer Disease(AD).
Tag	His
Products description	Recombinant Equine α-synuclein protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-a-synuclein-Ab01, GMP-EQU-a-synuclein-Ab02
Product Name	Anti-Equine α-synuclein mouse monoclonal antibody (mAb)
Target/Biomarker	Equine Alpha-synuclein (α-synuclein)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Equine Alpha-synuclein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-α-synuclein antibodies in α-synuclein level test of animal Equine/Horse with Alzheimer Disease(AD).
Tag	mFc
Products description	Anti-Equine α-synuclein mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-α-synuclein antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-a-synuclein-Ab03, GMP-EQU-a-synuclein-Ab04
Product Name	Anti-Equine α-synuclein human monoclonal antibody (mAb)
Target/Biomarker	Equine Alpha-synuclein (α-synuclein)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Recombinant Equine Alpha-synuclein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-α-synuclein antibodies in α-synuclein level test of animal Equine/Horse with Alzheimer Disease(AD).
Tag	hFc
Products description	Anti-Equine α-synuclein human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-α-synuclein antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Equine α-synuclein, a molecular counterpart to its human homologue, emerges as a captivating figure in the intricate tapestry of the equine nervous system. At its core, this protein is an intrinsically disordered marvel, defying conventional structural classifications. Structurally, it mirrors a "Janus-faced" molecule, featuring an amphipathic N-terminal segment, a central hydrophobic region, and a negatively charged C-terminal tail. This unique structural makeup hints at its versatile roles within the neuronal realm. Equine α-synuclein's primary abode lies within the central nervous system of horses, where it assumes an array of pivotal roles. Among its most notable functions is its influence on synaptic vesicle dynamics. It dynamically associates with synaptic vesicles, orchestrating their trafficking and modulating neurotransmitter release. This role positions Equine α-synuclein as a key conductor in the finely tuned orchestra of synaptic transmission. Beyond the mechanics of neurotransmission, Equine α-synuclein wields influence over synaptic plasticity, the cornerstone of learning and memory. Its presence regulates synaptic strength and orchestrates the molecular cascades that underpin adaptive changes in neural circuits. In this capacity, Equine α-synuclein emerges as a molecular architect of cognitive processes in horses. Yet, the intrigue surrounding Equine α-synuclein deepens when we delve into its propensity to aggregate, paralleling its human counterpart. Much like in humans, Equine α-synuclein can undergo conformational shifts leading to the formation of insoluble protein aggregates, Lewy bodies. These aggregates are central to the pathogenesis of neurodegenerative disorders, particularly in aging horses. Understanding the triggers and dynamics of this transition into aggregation-prone states is a focal point of research, as it holds the key to unraveling the mysteries of these debilitating diseases.

About GDU